Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes
derived from recurrently mutated driver genes. Here we describe a high-throughput platform …

A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of
functional, antigen-specific T cells within the tumor. Neoantigen-directed therapy is a …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …

Identifying neoepitopes that elicit an adaptive immune response is a major bottleneck to
developing personalized cancer vaccines. Experimental validation of candidate …

The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …

The identification of patient-specific tumor antigens is complicated by the low frequency of T
cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables …

The immunopeptidome is the set of peptides presented by the major histocompatibility
complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA) …

The success of cancer immunotherapy depends in part on the strength of antigen
recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen …